Former AstraZeneca Personalized Healthcare Strategy Leader Named Senior Vice President of Companion Diagnostics at DiaCarta
Richmond, California, May 13, 2021.
DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy, today announced the appointment of Hongjun “Harry” Yang, Ph.D., former Executive Personalized Healthcare Strategy Leader at AstraZeneca, as Senior Vice President of Companion Diagnostics (CDx) at DiaCarta.
Dr. Yang will lead the companion diagnostics team at DiaCarta where he will be instrumental in incorporating the XNA technology platform into the next generation treatment complementary companion diagnostics. At his previous role, Dr. Yang oversaw precision medicine programs at AstraZeneca, including the late clinical development and product launches of revolutionary anti-cancer drugs.
“Dr. Yang has followed DiaCarta’s clinical progress for years, and we are excited to have him lead our CDx programs. We look forward to strengthening our relationships with key opinion leaders and pharmaceutical companies who can benefit from DiaCarta’s technologies,” said Aiguo Zhang, Ph.D., Founder and CEO of DiaCarta.
Dr. Yang will present a webinar entitled “Precision Medicine for Non-Small Cell Lung Cancer,” providing an overview on lung cancer treatments to the audience Fighting Lung Cancer Online Forum, a WeChat group primarily consisting of physicians, on Saturday, May 15, 2021 at 6:00 p.m. PDT. This online forum is sponsored by the China Anti-Cancer Association (CACA). Dr. Yang’s presentation will focus on how the field of personalized medicine has evolved over time and developed with the help of companion diagnostics. In recent years, companion diagnostics have helped in identification and assessment of mutations affecting every individual patient, thereby aiding the prescription of the appropriate dose of a personalized therapy. Diagnostics assess the mutant affecting an individual patient so the appropriate personalized therapeutic can be confidently prescribed. The webinar will be accessible on Zoom via the Meeting ID: 982 501 2641 and the password of 2021.
“I am grateful for the opportunity to present to thousands of specialists across the globe in the lung cancer space. Significant progress has been made in the field, and we look forward to tracking the latest advancements as pharmaceutical companies progress promising targeted therapeutics through the clinical regulatory process. The recent clinical success of three companies on anti-KRAS drugs is promising. Companion diagnostics, such as the technologies developed by DiaCarta, are critical in the successful implementation of these treatments,” said Dr. Yang.
About DiaCarta Inc.
DiaCarta is a molecular diagnostics company that has developed innovative technologies that transform patient care by providing effective precision diagnostics using liquid biopsy. In addition to its FDA EUA approved QuantiVirus™ SARS-CoV-2 Tests, DiaCarta offers a range of testing services, from single-gene QClamp® qPCR tests to its OptiSeq™ XNA-NGS panels. The company is well positioned as a leader in the new ‘liquid biopsy’ In Vitro Diagnostics field with high-precision detection of ctDNA. Its novel XNA technology provides high level of sensitivity as it clamps the wild-type sequence and amplifies the mutant target sequence. Using this technology, the company has developed its highly sensitive, early detection ColoScape™ Colorectal Cancer test using blood. Powered by its SuperbDNA™ technology that provides high level of detection by amplifying the signal and requiring no RNA/DNA extraction or amplification, the company has developed its revolutionary RadTox™ test that personalizes radiation therapy, mitigates adverse events, and enhances patient care. Based in Richmond, California the company is ISO certified, GMP-compliant and offers CLIA certified laboratory services to its customers. www.diacarta.com
Richard Brand, CFO, DiaCarta
Olipriya Das, Ph.D., Russo Partners
DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy today announced that its new QuantiVirus™ SARS-CoV-2 Variant Detection Test received the CE/IVD marking and therefore, can now be commercialized within the EU and rest of the world. This new test screens for the SARS-CoV-2 virus and simultaneously identifies and differentiates all the new mutating COVID 19 variants including the Alpha (UK), Beta (S. Africa), Gamma (Brazil), Delta (India), Delta Plus (India), Epsilon (California) and the Kappa (India) variants.
DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy today announced the publication of a study entitled “A Rapid SARS-CoV-2 Variant Detection by Molecular-Clamping Based RT-qPCR” in MedRxiV that demonstrates the enhanced sensitivity and specificity using its proprietary XNA based Molecular Clamping Technology that uses innovative synthetic Xenonucleic acid molecular oligomers (XNA) that hybridize with target wild-type DNA sequences, acting as molecular clamps, to enable the accurate amplification of mutant sequences only, using quantitative real-time polymerase chain reactions (qPCR).
DiaCarta Announces Publication in Nature Scientific Reports Demonstrating cfDNA Biomarker Algorithm Predicts Response and Outcome of Chemotherapy
DiaCarta Inc., a precision molecular diagnostics company with proprietary technologies for the development of novel liquid biopsy oncology tests, announced today the publication of a study in Nature Scientific Reports that demonstrates that DiaCarta’s cfDNA biomarker algorithm could function as a prognostic biomarker and efficacy predictor for non-small cell lung cancer (NSCLC) patients.
According to the recent FDA SARS-CoV-2 Reference Panel Comparative Data released on September 15, among all the FDA EUA tests with returned results, DiaCarta’s QuantiVirusTM SARS-CoV-2 Test and QuantiVirus™ SARS-CoV-2 Multiplex Test both rank within the top 3 for product sensitivity.
DiaCarta’s QuantiVirus™ SARS-CoV-2 Multiplex Test ranks among the top 10 kits in terms of low limit of detection (LoD). DiaCarta is the top 6 company, after Perkin Elmer, Roche, Quest, RTA and BD Biosciences.